Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 5/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177564 | 0.95 | ABHD6 (0.50) | ABHD6NR1H2TMEM97SIGMAR1NAMPT | |
| SCHEMBL7850845 | 0.85 | NR1H2 (0.49) | ABHD6NR1H2TMEM97SIGMAR1NAMPT | |
| SCHEMBL15624172 | 0.83 | ABHD6 (0.52) | ABHD6NR1H2TMEM97SIGMAR1ESR2 | |
| SCHEMBL1285596 | 0.82 | NR1H2 (0.69) | ABHD6NR1H2TMEM97SIGMAR1NAMPT | |
| SCHEMBL29407557 | 0.82 | NR1H2 (0.69) | ABHD6NR1H2TMEM97SIGMAR1NAMPT | |
| SCHEMBL6102363 | 0.79 | ABHD6 (0.68) | ABHD6ACEMEN1KMT2AHRH3 | |
| SCHEMBL27914873 | 0.79 | NAMPT (0.49) | NR1H2TMEM97SIGMAR1NAMPTESR2 | |
| SCHEMBL3176570 | 0.79 | ABHD6 (0.47) | ABHD6TMEM97SIGMAR1ESR2 | |
| SCHEMBL14117003 | 0.77 | ABHD6 (0.53) | ABHD6NR1H2ESR2MEN1KMT2A | |
| SCHEMBL12408702 | 0.77 | ESR2 (0.67) | ABHD6NR1H2TMEM97SIGMAR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166176-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| EP-2262496-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009105715-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166176-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | ABHD6 863/4885NR1H2 38/4885TMEM97 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.